ALL COMPANIES

Company 1

Management

Steven H. Rouhandeh - Chairman of the board and Executive Chairman

Tim Miller, Ph.D. - President and Chief Executive Officer, Director

Jeffrey B. Davis - Chief Operating Officer, Director

Summary

The company was formerly known as Access Pharmaceuticals and was founded in Dallas in 1989. In 2013 company changed its name to PlasmaTech Biopharmaceuticals and in 2014 acquired Cleveland based company Abeona Therapeutics. In 2015 PlasmaTech decided to adopt the name of its formerly acquired company and changed name to its current Abeona Therapeutics.

Company focuses on Gene Therapies and Plasma based products to cure rare diseases. Abeona’s stock is traded on NASDAQ. Company is dedicated to cure rare and orphan diseases. Currently company does not have any marketed products, however possesses a portfolio of products that are now under clinical trials. Diseases that are targeted include Mucopolysaccharidosis, Juvenile Batten Disease, Fanconi Anemia.  Company aims for accelerated regulatory paths because of orphan, rare, pediatric disease designation.

Strategies

Company is dedicated to cure rare and orphan diseases. Currently company does not have any marketed products, but possesses a portfolio of products that are now under clinical trials targeting several rare and orphan diseases including Mucopolysaccharidosis, Juvenile Batten Disease, Fanconi Anemia.  Company aims at accelerated regulatory paths because of orphan, rare, pediatric disease designation.

Analysis

Company has a good history of operation since 1989 with experienced board of directors and robust core management team spanning multiple fields of activity. Company adopted very attractive accelerated regulatory path and its products are highly innovative given that no effective treatments for its target diseases are available. Company holds a number of attractive therapy candidates in its pipeline, although only one of which has passed Phase I/II.

Strengths:

  • Company with good history of operations with strong team of directors and management
  • Robust pipeline of products
  • Successful history of acquisition and former financing rounds
  • Viable business model of providing orphan and rare pediatric diseases

Weaknesses:

  • No product available on the market yet
  • No significant operating revenue streams
  • Limited experience in manufacturing in clinical and commercial quantities

Opportunities:

  • Successful launch of orphan disease therapies
  • Good regulatory landscape for registration paths
  • Favourable deals with NHS regarding delivering treatments to patients

Threats:

  • Unsuccessful translation of potential therapies
  • Not developing market for such a specific group of patients
  • Failing clinical trials

Funding Received: $38.43 M (collectively as Access, PlasmaTech and Abeona)

Last Round: $8.5 M

IPO / Stock: Jan 10, 2003 / OTCBB:ACCP (as Access Pharmaceuticals) Dec 18, 2014/

NASDAQ:PTBI (currently NASDAQ:ABEO)

Revenue 2015/2014: $40.57 M/ $11.55 M

Number of Clinical/Preclinical Trials: 2/1

AGING ANALYTICS – INVEST FOR LIFE
info@aginganalytics.com
AGING ANALYTICS 2016